Get started
CHINA RESOURCES PHARMACEUTICAL GRCC

CHINA RESOURCES PHARMACEUTICAL GR

5.34HKDD
−0.03−0.56%
As of today at 03:59 GMT
HKD
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals

3320 fundamentals

Key facts

Market capitalization‪33.99 B‬HKD
Dividend yield (indicated)2.71%
Price to earnings Ratio (TTM)9.29
Basic EPS (TTM)0.58HKD
Founded1938
Employees (FY)‪72.7 K‬
CEO—
Websitecrpharm.com
About

China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. It operates through the following segments: Manufacturing, Distribution, Retail, and Others. The Manufacturing segment handles the research and development, manufacture, and sale of pharmaceutical and healthcare products. The Distribution segment focuses on the distribution, warehousing, logistics, and pharmaceutical supply chain solutions and services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. The Retail segment deals with the operation of retailing of pharmacy stores. The Others segment comprises of property holding. The company was founded in 1938 and is headquartered in Hong Kong.

Ownership
‪‪6.28 B‬‬
Closely held shares
‪‪4.46 B‬‬ (71.04%)
Free Float shares
‪‪1.82 B‬‬ (28.96%)
Closely held shares
‪‪4.46 B‬‬ (71.04%)
Free Float shares
‪‪1.82 B‬‬ (28.96%)
Capital structure
Market cap
‪‪33.99 B‬‬
Debt
‪‪93.16 B‬‬
Minority interest
‪‪53.04 B‬‬
Cash & equivalents
‪‪36.56 B‬‬
Enterprise value
‪‪143.64 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪33.99 B‬‬
Price to earning ratio (P/E)
9.29x
Price to sales ratio (P/S)
0.12x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
9.29x
Price to sales ratio (P/S)
0.12x
Valuation ratios
‪0.00‬
‪0.04‬
‪0.09‬
‪0.14‬
‪0.18‬
H1 '22
H2 '22
H1 '23
H1 '24
H2 '24
‪0.00‬
‪3.00‬
‪6.00‬
‪9.00‬
‪12.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪0.55%‬
‪1.05%‬
‪1.55%‬
‪2.05%‬
‪2.55%‬
H1 '22
H2 '22
H1 '23
H1 '24
H2 '24
‪0.00‬
‪‪40.00 B‬‬
‪‪80.00 B‬‬
‪‪120.00 B‬‬
‪‪160.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪40.00 B‬‬
‪‪80.00 B‬‬
‪‪120.00 B‬‬
‪‪160.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪40.00 B‬‬
‪‪80.00 B‬‬
‪‪120.00 B‬‬
‪‪160.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Distribution
Manufacturing
Retail
Other
By country
Period: 2024
China
Other

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H2 '22
H1 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪‪40.00 B‬‬
‪‪80.00 B‬‬
‪‪120.00 B‬‬
‪‪160.00 B‬‬
Actual
Estimate
Earnings
Next:Aug 21, 2025
H2 '22
H1 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪0.13‬
‪0.26‬
‪0.39‬
‪0.52‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
25.39%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
2.71%
Last payment
0.056
Last ex-date
May 28, 2025
Last pay date
Jul 14, 2025
Dividend history
‪2.5%‬
‪3.0%‬
‪3.5%‬
‪4.0%‬
‪4.5%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.04‬
‪0.09‬
‪0.14‬
‪0.18‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
H1 '22
H2 '22
H1 '23
H1 '24
H2 '24
‪‪−35.00 B‬‬
‪0.00‬
‪‪35.00 B‬‬
‪‪70.00 B‬‬
‪‪105.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪50.00 B‬‬
‪‪100.00 B‬‬
‪‪150.00 B‬‬
‪‪200.00 B‬‬
Assets
Liabilities